Author

Megan Stevens

University of ExeterORCID 0000-0002-7474-6759Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Organism:Drosophila· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Sebastian OlteaniD· 2 shared Benjamin E. HousdeniD· 1 shared Monica Ayine· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

3 top collaborators · 2 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Sebastian OlteanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyOncogenesisPeer-reviewedAug 21, 2026

A novel combinatorial treatment for Neurofibromatosis type 1 tumours revealed through cross-species genetic analysis

Megan Stevens, Sebastian Oltean, Benjamin E. Housden

This paper identifies AZT as a potential therapeutic for NF1 tumors through cross-species genetic analysis and validates its efficacy in human and mouse models.

DOI 10.1038/s41389-026-00643-z

Drosophilahuman

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintNov 27, 2025

Mechanistic analysis of compounds that modulate VEGF-A splicing in podocytes with therapeutic potential for diabetic nephropathy

Monica Ayine, Megan Stevens, Sebastian Oltean

This study identifies three compounds that increase VEGF-A165b expression in podocytes by modulating splicing through CLK1 kinase, suggesting CLK1 activation as a potential therapeutic strategy for diabetic nephropathy.

DOI 10.1101/2025.11.27.690981

humanbulk RNA-seq

𝕏 PostBluesky